Botensilimab

Botensilimab (AGEN 1181), a human anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) monoclonal antibody, is an innate and adaptive immune activator. Botensilimab can be used for the research of cancer[1].

Product Specifications

CAS Number

[2408310-37-0]

Product Name Alternative

AGEN 1181

UNSPSC

12352203

Target

CTLA-4

Type

Inhibitory Antibodies

Related Pathways

Immunology/Inflammation

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/botensilimab.html

Purity

99.00

Solubility

H2O

Smiles

[Botensilimab]

Molecular Weight

(144.54 kDa)

References & Citations

[1]Delepine C, et, al. 470 Botensilimab, an Fc-enhanced CTLA-4 antibody, enhances innate and adaptive immune activation to promote superior anti-tumor immunity in cold and I-O refractory tumors FREE.